Literature DB >> 12829033

Therapeutic drug monitoring in the treatment of HIV-infection.

John G Gerber1, Edward P Acosta.   

Abstract

The use of therapeutic drug monitoring (TDM) in the treatment of HIV-infection is gaining momentum in resource-rich countries. However, data justifying its use is still in short supply. In this manuscript we review the necessary components of TDM before it should be implemented in widespread clinical use. In addition, we provide specific examples of clinical situations where TDM is likely to useful. The overall conclusion of this review is that TDM is a promising therapeutic modality for improving antiretroviral efficacy and reducing toxicity. However, more prospective clinical trials are necessary in order to validate the therapeutic concentrations of antiretroviral drugs suggested by various investigators. In addition, both the clinical utility and cost effectiveness of TDM will need to be demonstrated by well-designed and adequately powered clinical trials in both antiretroviral nai;ve and experienced subjects. At this point in time we consider TDM in the treatment of HIV-infection as experimental with significant promise for the future.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829033     DOI: 10.1016/s1386-6532(03)00033-7

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  8 in total

Review 1.  Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs.

Authors:  Jennifer J Kiser; Peter L Anderson; John G Gerber
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

2.  Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.

Authors:  Qing Ma; Barry S Zingman; Amneris E Luque; Margaret A Fischl; Barbara M Gripshover; Charles S Venuto; Robin DiFrancesco; Alan Forrest; Gene D Morse
Journal:  Ther Drug Monit       Date:  2011-06       Impact factor: 3.681

Review 3.  Clinically relevant drug-drug interactions between antiretrovirals and antifungals.

Authors:  Ramya Krishna Vadlapatla; Mitesh Patel; Durga K Paturi; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-02-12       Impact factor: 4.481

4.  Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.

Authors:  Marian Iwamoto; Larissa A Wenning; Amelia S Petry; Martine Laethem; Marina De Smet; James T Kost; Sheila A Breidinger; Eric C Mangin; Neal Azrolan; Howard E Greenberg; Wouter Haazen; Julie A Stone; Keith M Gottesdiener; John A Wagner
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

5.  Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir.

Authors:  O Janneh; R C Hartkoorn; E Jones; A Owen; S A Ward; R Davey; D J Back; S H Khoo
Journal:  Br J Pharmacol       Date:  2008-08-18       Impact factor: 8.739

Review 6.  Current practices in laboratory monitoring of HIV infection.

Authors:  Madhu Vajpayee; Teena Mohan
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

7.  HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.

Authors:  Adriaan E Basson; Salome Charalambous; Christopher J Hoffmann; Lynn Morris
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

8.  Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture.

Authors:  Elijah Paintsil; Susan P Grill; Ginger E Dutschman; Yung-Chi Cheng
Journal:  AIDS Res Ther       Date:  2009-04-22       Impact factor: 2.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.